Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

npj Breast Cancer

August 29, 2022

10.1038/s41523-022-00467-1

Cited by 103

Related Papers

No related papers found

Powered by citation graph analysis